Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research
_↗ alamarbio.com
News Image

Human Longevity, Inc. (HLI), a leading company in precision health and longevity, has announced a new strategic partnership with Alamar Biosciences a company focused on highly precise proteomics for disease detection. This collaboration will allow Human Longevity to introduce new proteomic testing services to further the science of human longevity. The initiative will integrate two of Alamar's advanced NULISAseq panels into HLI’s service offerings.

The first panel is the NULISAseq Inflammation Panel 250, which is designed to precisely detect and monitor chronic inflammation. This is a critical factor in aging and many age-related diseases. The second panel is the NULISAseq CNS Disease Panel 120, which focuses on the early detection and monitoring of key biomarkers related to neurodegenerative and neurological disorders. This panel will offer unprecedented insight into the health and resilience of the brain.

By combining Alamar’s ultra-sensitive NULISA proteomics platform with HLI's extensive experience in analyzing genomics, imaging, and multi-omics data from over 10,000 clients, clinicians and researchers will have access to powerful new tools. These tools are specifically designed to measure biological processes that directly influence both healthspan and lifespan.

Dr. Wei-Wu He, Executive Chairman of Human Longevity, highlighted that proteomics is the "next frontier" in longevity medicine, and this partnership with Alamar will help move towards truly predictive and preventative healthcare by adding high-resolution protein measurements to their current platform. Yuling Luo, PhD, CEO of Alamar Biosciences, expressed pride in the collaboration, noting that HLI’s choice of their platform underscores its value in driving real-world applications that support longer, healthier lives.

The new panels will be integrated into HLI’s Executive Health and 100+ Longevity precision health programs later this year, initially for current members. This collaboration highlights the shared commitment of both companies to advancing longevity science through the use of AI, multi-omics, and next-generation diagnostics. Human Longevity, founded in 2013, is a biotechnology leader focused on extending human healthspan through data-driven evaluations. Alamar Biosciences is a privately held life sciences company dedicated to enabling the earliest detection of disease with its proprietary NULISA Platform, which offers detection sensitivity far beyond current market technologies.

Log In
Sign Up